Cargando…

CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma

SIMPLE SUMMARY: Circular RNA (circRNA) plays an important role in cancer, but little is known about its role in clear cell renal cell carcinoma (ccRCC). The study was designed to analyze the role of circRNAs in ccRCC. We show that circEHD2, circENGLN3, and circNETO2 are upregulated in ccRCC compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Lisa, Klümper, Niklas, Schmidt, Doris, Kristiansen, Glen, Toma, Marieta, Ritter, Manuel, Alajati, Abdullah, Ellinger, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124893/
https://www.ncbi.nlm.nih.gov/pubmed/33946584
http://dx.doi.org/10.3390/cancers13092177
_version_ 1783693341618077696
author Frey, Lisa
Klümper, Niklas
Schmidt, Doris
Kristiansen, Glen
Toma, Marieta
Ritter, Manuel
Alajati, Abdullah
Ellinger, Jörg
author_facet Frey, Lisa
Klümper, Niklas
Schmidt, Doris
Kristiansen, Glen
Toma, Marieta
Ritter, Manuel
Alajati, Abdullah
Ellinger, Jörg
author_sort Frey, Lisa
collection PubMed
description SIMPLE SUMMARY: Circular RNA (circRNA) plays an important role in cancer, but little is known about its role in clear cell renal cell carcinoma (ccRCC). The study was designed to analyze the role of circRNAs in ccRCC. We show that circEHD2, circENGLN3, and circNETO2 are upregulated in ccRCC compared with non-malignant renal tissue. Increased circEHD2 levels were significant and independent predictors of progression-free and cancer-specific survival of ccRCC patients. Thus, the analysis of circRNAs may be of diagnostic and prognostic relevance in patients with ccRCC. ABSTRACT: Background: Circular RNA (circRNA) plays an important role in the carcinogenesis of various tumors. It is assumed that circRNAs have a high tissue and tumor specificity, thus they are discussed as cancer biomarkers. The knowledge about circRNAs in clear cell renal carcinoma (ccRCC) is limited so far, and thus we studied the expression profile of seven circRNAs (circCOL5A1, circEHD2, circEDEM2, circEGNL3, circNETO2, circSCARB1, circSOD2) in a cohort of ccRCC patients. Methods: Fresh-frozen normal and cancerous tissues were prospectively collected from patients with ccRCC undergoing partial/radical nephrectomy. Total RNA was isolated from 121 ccRCC and 91 normal renal tissues, and the circRNA expression profile was determined using quantitative real-time PCR. Results: circEHD2, circENGLN3, and circNETO2 were upregulated in ccRCC compared with non-malignant renal tissue. circENGLN3 expression was highly discriminative between normal and cancerous tissue. None of the circRNAs was correlated with clinicopathological parameters. High circEHD2 and low circNETO2 levels were an independent predictor of a shortened progression-free survival, cancer-specific survival, and overall survival in patients with ccRCC undergoing nephrectomy. Conclusions: The analysis of circRNAs may provide diagnostic and prognostic information. Thus, circRNAs could help to optimize the individual treatment and ultimately improve ccRCC patients’ survival.
format Online
Article
Text
id pubmed-8124893
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81248932021-05-17 CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma Frey, Lisa Klümper, Niklas Schmidt, Doris Kristiansen, Glen Toma, Marieta Ritter, Manuel Alajati, Abdullah Ellinger, Jörg Cancers (Basel) Article SIMPLE SUMMARY: Circular RNA (circRNA) plays an important role in cancer, but little is known about its role in clear cell renal cell carcinoma (ccRCC). The study was designed to analyze the role of circRNAs in ccRCC. We show that circEHD2, circENGLN3, and circNETO2 are upregulated in ccRCC compared with non-malignant renal tissue. Increased circEHD2 levels were significant and independent predictors of progression-free and cancer-specific survival of ccRCC patients. Thus, the analysis of circRNAs may be of diagnostic and prognostic relevance in patients with ccRCC. ABSTRACT: Background: Circular RNA (circRNA) plays an important role in the carcinogenesis of various tumors. It is assumed that circRNAs have a high tissue and tumor specificity, thus they are discussed as cancer biomarkers. The knowledge about circRNAs in clear cell renal carcinoma (ccRCC) is limited so far, and thus we studied the expression profile of seven circRNAs (circCOL5A1, circEHD2, circEDEM2, circEGNL3, circNETO2, circSCARB1, circSOD2) in a cohort of ccRCC patients. Methods: Fresh-frozen normal and cancerous tissues were prospectively collected from patients with ccRCC undergoing partial/radical nephrectomy. Total RNA was isolated from 121 ccRCC and 91 normal renal tissues, and the circRNA expression profile was determined using quantitative real-time PCR. Results: circEHD2, circENGLN3, and circNETO2 were upregulated in ccRCC compared with non-malignant renal tissue. circENGLN3 expression was highly discriminative between normal and cancerous tissue. None of the circRNAs was correlated with clinicopathological parameters. High circEHD2 and low circNETO2 levels were an independent predictor of a shortened progression-free survival, cancer-specific survival, and overall survival in patients with ccRCC undergoing nephrectomy. Conclusions: The analysis of circRNAs may provide diagnostic and prognostic information. Thus, circRNAs could help to optimize the individual treatment and ultimately improve ccRCC patients’ survival. MDPI 2021-04-30 /pmc/articles/PMC8124893/ /pubmed/33946584 http://dx.doi.org/10.3390/cancers13092177 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frey, Lisa
Klümper, Niklas
Schmidt, Doris
Kristiansen, Glen
Toma, Marieta
Ritter, Manuel
Alajati, Abdullah
Ellinger, Jörg
CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title_full CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title_fullStr CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title_full_unstemmed CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title_short CircEHD2, CircNETO2 and CircEGLN3 as Diagnostic and Prognostic Biomarkers for Patients with Renal Cell Carcinoma
title_sort circehd2, circneto2 and circegln3 as diagnostic and prognostic biomarkers for patients with renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124893/
https://www.ncbi.nlm.nih.gov/pubmed/33946584
http://dx.doi.org/10.3390/cancers13092177
work_keys_str_mv AT freylisa circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT klumperniklas circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT schmidtdoris circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT kristiansenglen circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT tomamarieta circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT rittermanuel circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT alajatiabdullah circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma
AT ellingerjorg circehd2circneto2andcircegln3asdiagnosticandprognosticbiomarkersforpatientswithrenalcellcarcinoma